?
Vogt Susan L N
Director
Anika Therapeutics, Inc.
US, Bedford [HQ]
CIK
1191270
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
23,778
Price per Share :
$16.19
Equivalence :
$384,965.82
Transaction History
-
A23,778 Shares After TransactionValue : $n/a$0.0Transaction Date : 06/08/22
-
Footnotes
-
-
Footnotes:#1 These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2023 annual meeting of the Company's stockholders or June 8, 2023.
-
A30,278 Shares After TransactionValue : $n/a$0.0Transaction Date : 06/14/23
-
Footnotes
-
-
Footnotes:#1 These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024.
-
A36,049 Shares After TransactionValue : $n/a$0.0Transaction Date : 07/09/24
-
Footnotes
-
-
Footnotes:#1 These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025.
-
A43,065 Shares After TransactionValue : $n/a$0.0Transaction Date : 10/01/21
-
Footnotes
-
-
Footnotes:#1 Grant of restricted shares for the Company's common stock issued under 2010 Sharps Compliance Stock Plan per Sharps Compliance Non-Employee Directors and Committee Compensation. The grant represents the equity portion of the non-employee director and committee compensation services to be provided October 1, 2021 - September 30, 2022. The restricted shares are subject to the terms and conditions of the underlying Restricted Stock Award Agreement and vest 25% on each of December 31, 2021; March 31, 2022; June 30, 2022 and September 30, 2022.#2 Amount of securities beneficially owned following the reported transaction includes Common Stock and Restricted Stock Awards.
-
U43,065 Shares After TransactionValue : $376,818.75$376,818.75Transaction Date : 08/22/22
-
Footnotes
-
-
Footnotes:#1 Amount of securities beneficially owned in the reported transaction includes issued and outstanding shares of common stock (the "Common Stock") of Sharps Compliance Corp. (the "Company") and issued and outstanding unvested restricted stock awards granted under the Sharps Compliance Corp. 2010 Stock Plan, as amended.#2 On July 12, 2022, the Company entered into that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Company, Raven Buyer, Inc., a Delaware corporation ("Parent"), and Raven Houston Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Raven Buyer, Inc. ("Purchaser"), pursuant to which, on July 25, 2022, Purchaser commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of the Common Stock for a purchase price of $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding.#3 Due to a 1000 character limit, Footnote 3 is a continuation of Footnote 2. On August 22, 2022, Purchaser accepted all shares tendered in the Offer. On August 23, 2022, Purchaser merged with and into the Company (the "Merger") and the Company ceased to be a public company. Pursuant to the Merger Agreement, each share of Common Stock (including each restricted stock award, whether or not vested), that was outstanding immediately prior to the consummation of the Merger was automatically cancelled and, in exchange therefor, the holder is entitled to receive $8.75 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding.